| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1085640578 |
| P356 | DOI | 10.1038/S41598-017-02483-9 |
| P8608 | Fatcat ID | release_ozx5yczysjhkzak3kmzpj7nbo4 |
| P932 | PMC publication ID | 5454031 |
| P698 | PubMed publication ID | 28572590 |
| P50 | author | Clemens Reinshagen | Q85366949 |
| Jérémie Roux | Q39715373 | ||
| P2093 | author name string | Sean E Lawler | |
| Khalid Shah | |||
| Yanni Zhu | |||
| Deepak Bhere | |||
| Michal O Nowicki | |||
| Nicole Bassoff | |||
| P2860 | cites work | Small nanobody drugs win big backing from pharma. | Q54645549 |
| Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma | Q63859552 | ||
| Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer | Q79370322 | ||
| Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab | Q24600031 | ||
| Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies | Q26852366 | ||
| A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies | Q27675148 | ||
| Structural Evaluation of EGFR Inhibition Mechanisms for Nanobodies/VHH Domains | Q27678732 | ||
| Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme | Q27824801 | ||
| EGFR mutation and resistance of non-small-cell lung cancer to gefitinib | Q27824829 | ||
| KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. | Q27824867 | ||
| Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 | ||
| A unified model for apical caspase activation | Q28609101 | ||
| EGF-ERBB signalling: towards the systems level | Q29619032 | ||
| Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) | Q29620605 | ||
| In vitro efficacy of immuno-chemotherapy with anti-EGFR human Fab-Taxol conjugate on A431 epidermoid carcinoma cells | Q33286025 | ||
| Tumor associated macrophages protect colon cancer cells from TRAIL-induced apoptosis through IL-1beta-dependent stabilization of Snail in tumor cells | Q33641541 | ||
| EGFR and cancer prognosis | Q34399312 | ||
| Targeting death and decoy receptors of the tumour-necrosis factor superfamily | Q34791120 | ||
| Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas | Q35827956 | ||
| A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma | Q35967192 | ||
| Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. | Q36339837 | ||
| Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas | Q36695971 | ||
| Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy | Q37140126 | ||
| Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo | Q37226145 | ||
| TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation | Q37286884 | ||
| Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors | Q37447217 | ||
| Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. | Q37593624 | ||
| Death receptor agonists as a targeted therapy for cancer | Q37701624 | ||
| Targeting tumors with nanobodies for cancer imaging and therapy. | Q38137610 | ||
| Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384. | Q39012877 | ||
| A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity | Q39133025 | ||
| Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy | Q39399346 | ||
| A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. | Q39552974 | ||
| Potent tumor tropism of induced pluripotent stem cells and induced pluripotent stem cell-derived neural stem cells in the mouse intracerebral glioma model | Q39611660 | ||
| A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy. | Q39744489 | ||
| Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model | Q39988659 | ||
| PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib | Q40033522 | ||
| TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. | Q40109387 | ||
| Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression | Q40169741 | ||
| Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab | Q40240054 | ||
| Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR | Q40619097 | ||
| Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. | Q40789234 | ||
| Ubiquitin-specific protease 8 links the PTEN-Akt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity in glioblastoma multiforme | Q41387216 | ||
| Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. | Q41811594 | ||
| Activation and specificity of human caspase-10. | Q42423646 | ||
| Structural basis for inhibition of the epidermal growth factor receptor by cetuximab | Q45345151 | ||
| Patterns of care for adults with newly diagnosed malignant glioma. | Q46214511 | ||
| Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling | Q46580419 | ||
| Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety | Q46661382 | ||
| In vivo tracking of neural progenitor cell migration to glioblastomas | Q48209565 | ||
| Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. | Q50337140 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2602 | |
| P577 | publication date | 2017-06-01 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors | |
| P478 | volume | 7 |
| Q96303214 | A Novel Anti-Kv10.1 Nanobody Fused to Single-Chain TRAIL Enhances Apoptosis Induction in Cancer Cells |
| Q90241548 | Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy |
| Q45706786 | Correlation between STK33 and the pathology and prognosis of lung cancer |
| Q92043370 | Glioblastoma cells vampirize WNT from neurons and trigger a JNK/MMP signaling loop that enhances glioblastoma progression and neurodegeneration |
| Q48117495 | Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies. |
| Q91716512 | Molecular Mode of Action of TRAIL Receptor Agonists-Common Principles and Their Translational Exploitation |
| Q47099672 | Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics. |
| Q90083187 | Reversion of tumor hepatocytes to normal hepatocytes during liver tumor regression in an oncogene-expressing transgenic zebrafish model |
| Q52362264 | Single-Domain Antibodies and the Promise of Modular Targeting in Cancer Imaging and Treatment. |
| Q97901404 | TRAIL of Hope Meeting Resistance in Cancer |
Search more.